Author Topic: Covid Culture (was Outbreak Culture)  (Read 32911 times)

0 Members and 0 Guests are viewing this topic.

Offline waldo

  • Full Member
  • ***
  • Posts: 4808
Re: Covid Culture (was Outbreak Culture)
« Reply #2895 on: February 25, 2021, 12:19:31 pm »
You think people should be praising yer boy for this sad state of affairs?   I'm not going to pump his tires; that's your job.

what sad state of affairs... be specific, be precise as to what you're labeling as a vaccine procurement failure... I appreciate you have difficulty with specificity and preciseness, but give it a try, hey!

I posted last week saying that I didn't think it was fair to put all the blame on JT and the Sunshine Gang, that's about the most enthusiastic praise I can muster. Canadians will still be waiting for vaccines well after other advanced nations have reached the levels required to start reopening. I'm not sure what positive comment you think is warranted.

citation request to support your statement/claim - yes?

That the CanSino vaccine apparently sucks doesn't make JT look any smarter for having gambled on those magic beans in the first place.

what gamble? On a Phase 3 clinical trial where its said Canada doesn't have the 'disease burden' to support running a Phase 3 trial. The founder & CEO of CanSino said as much... and this was reaffirmed in recent days by University of Ottawa School of Epidemiology and Public Health Prof. Amir Attaran when he was asked about the presumed ability of the company Providence to be able to run Phase 2/3 trials in Canada; as I previously quoted:
"Providence delivering a vaccine by Dec. 31 is so improbable as to belong in the realm of fantasy in my opinion," said Attaran.

He doubts Providence will be able to enrol sufficient participants in its Phase 2 and Phase 3 trials, which have yet to be approved by Health Canada.

as early as August, 2020: the federal Liberal government had announced vaccine agreements with 4 manufacturers. Of course, as was the global situation facing all countries, at that time no Phase 3 trials had been completed by any company, no vaccine approvals had been given by any country. This proactive move by the Canadian government was one of speculation... presuming on the positive results of final trials and that the results would be sanctioned/approved by medical agencies/organizations. And you expected what exactly... in August of 2020? Your expectations were what?

We've found out since then that the shipment was blocked by China's Customs agency, not over concerns about whether Canada was suitable for trials.

 ;D well that would probably be the agency... that would practically extend upon the statements I offered. Do you have anything you can cite that actually counters what I stated. Per your norm you somehow fail to include the full context/statement as you self-servingly pick what you quote; here actually try to counter this full statement with a substantive citation/reference:
in any case, some interesting comments have recently come forward from the founder & CEO of CanSinoBIO, Xuefeng Yu. If you don't know, Yu's story in why he originally left China, got his Ph.D. from McGill, then worked 20+ years in the Canadian biopharmaceutical industry... suggests his comments are not politically motivated.

Yu suggests decisions in China on whether to send the vaccine to Canada were “caught in bureaucratic indecision” that occurred right after the Chinese government changed the process for shipping vaccines out of the country subsequent to the signing of Canada's NRC agreement with CanSino. Additionally, there was questioning on the "value add" of the proposed Canadian trial since CanSinoBIO had already completed Phase 1 and Phase 2 trials in China... and, as Yu highlights, Canada lacks a "high disease burden" required for Phase 3 trials:

Quote from: Xuefeng Yu - founder and CEO of CanSinoBIO
In citing the comparatively small number of COVID-19 cases in Canada: "Canada is not an ideal place to run phase three"

in any case, CanSinoBIO moved on to sign partnership agreements with companies in Russia, South America and East Africa - where that so-called, "heavy disease burden" suitable for Phase 3 trials exists.